DE60237372D1 - Magenretentionssystem mit kontrollierter arzneimittelfreisetzung - Google Patents
Magenretentionssystem mit kontrollierter arzneimittelfreisetzungInfo
- Publication number
- DE60237372D1 DE60237372D1 DE60237372T DE60237372T DE60237372D1 DE 60237372 D1 DE60237372 D1 DE 60237372D1 DE 60237372 T DE60237372 T DE 60237372T DE 60237372 T DE60237372 T DE 60237372T DE 60237372 D1 DE60237372 D1 DE 60237372D1
- Authority
- DE
- Germany
- Prior art keywords
- core
- drug
- release
- retention system
- controlled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000014759 maintenance of location Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 230000002496 gastric effect Effects 0.000 abstract 3
- 239000012530 fluid Substances 0.000 abstract 2
- 230000002051 biphasic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000008199 coating composition Substances 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 239000000599 controlled substance Substances 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000008961 swelling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN612MU2001 | 2001-07-04 | ||
PCT/IN2002/000144 WO2003011255A1 (en) | 2001-07-04 | 2002-07-04 | Gastric retention controlled drug delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60237372D1 true DE60237372D1 (de) | 2010-09-30 |
Family
ID=32051199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60237372T Expired - Lifetime DE60237372D1 (de) | 2001-07-04 | 2002-07-04 | Magenretentionssystem mit kontrollierter arzneimittelfreisetzung |
Country Status (17)
Country | Link |
---|---|
US (2) | US7776345B2 (de) |
EP (2) | EP1411901B1 (de) |
JP (2) | JP4994570B2 (de) |
KR (1) | KR20040018394A (de) |
CN (1) | CN1520286B (de) |
AT (1) | ATE477795T1 (de) |
AU (1) | AU2002355686B2 (de) |
BR (1) | BR0211317A (de) |
CA (1) | CA2452738C (de) |
DE (1) | DE60237372D1 (de) |
ES (1) | ES2398348T3 (de) |
HU (1) | HUP0500795A3 (de) |
MX (1) | MXPA03012041A (de) |
PL (1) | PL370793A1 (de) |
RU (1) | RU2325152C2 (de) |
WO (1) | WO2003011255A1 (de) |
ZA (1) | ZA200400799B (de) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
KR20040016882A (ko) * | 2001-06-11 | 2004-02-25 | 제노포트 인코포레이티드 | 감소된 독성을 가진 gaba 유사체 프로드러그의 구강투여용 투여 형태물 |
EP1411901B1 (de) * | 2001-07-04 | 2010-08-18 | Sun Pharma Advanced Research Company Ltd | Magenretentionssystem mit kontrollierter arzneimittelfreisetzung |
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
TWI312285B (en) * | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
CA2486794A1 (en) * | 2002-06-04 | 2003-12-11 | J. B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical composition for controlled drug delivery system |
AR040682A1 (es) | 2002-07-25 | 2005-04-13 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
EP2354120A1 (de) | 2003-08-20 | 2011-08-10 | XenoPort, Inc. | Synthese von Acyloxyalkylcarbamat-Prodrugs und Zwischenprodukten davon |
BRPI0413756A (pt) | 2003-08-20 | 2006-10-31 | Xenoport Inc | composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica |
JP5686494B2 (ja) * | 2003-08-29 | 2015-03-18 | シオノギ インコーポレイテッド | 抗生物質製剤、その使用法及び作成方法 |
CN1929823A (zh) * | 2003-12-12 | 2007-03-14 | 宾韦斯特医药公司 | 托塞米缓释剂型 |
WO2005060942A1 (en) * | 2003-12-19 | 2005-07-07 | Aurobindo Pharma Ltd | Extended release pharmaceutical composition of metformin |
TW200533391A (en) * | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
AU2005269416B2 (en) | 2004-07-26 | 2011-07-28 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
KR20070050081A (ko) | 2004-08-13 | 2007-05-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도 |
FR2874325B1 (fr) * | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine |
DE102004042139B4 (de) * | 2004-08-31 | 2009-06-10 | Aristocon Verwaltungs- Gmbh | Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit |
US20080020041A1 (en) * | 2004-10-19 | 2008-01-24 | Ayres James W | Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid |
WO2006050472A2 (en) | 2004-11-03 | 2006-05-11 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids |
US7566738B2 (en) | 2004-11-03 | 2009-07-28 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use |
CN102429882B (zh) | 2004-11-04 | 2015-03-25 | 什诺波特有限公司 | 加巴喷丁前体药物持续释放口服剂型 |
ES2540929T3 (es) | 2005-02-01 | 2015-07-14 | Emisphere Technologies, Inc. | Sistema de administración de retención gástrica y liberación controlada |
EP1690540A1 (de) * | 2005-02-15 | 2006-08-16 | Neuro3D | Zusammensetzung enthaltend Ocaperidon |
US8431156B2 (en) * | 2005-02-22 | 2013-04-30 | Sun Pharma Advanced Research Company Ltd. | Pharmaceutical composition |
AU2006216696B2 (en) | 2005-02-23 | 2011-08-18 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
ATE396710T1 (de) * | 2005-07-19 | 2008-06-15 | Ethypharm Sa | Gastroretentive zusammensetzungen und verfahren zur herstellung |
EP1957052A2 (de) * | 2005-10-25 | 2008-08-20 | Pharmascience Inc. | System zur abgabe eines magenretentionsmittels |
US20090176882A1 (en) * | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
AU2007201808B8 (en) * | 2006-04-26 | 2013-09-05 | Sun Pharmaceutical Advanced Research Company Ltd | A method for alleviating signs and symptoms of spasticity |
US8703191B2 (en) * | 2006-07-25 | 2014-04-22 | Intelgenx Corp. | Controlled-release pharmaceutical tablets |
EP2049123B2 (de) | 2006-08-03 | 2016-08-24 | Horizon Pharma AG | Behandlung von rheumatoiden erkrankungen mit einem glucocorticoid mit verzögerter freisetzung |
CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
US20100016310A1 (en) * | 2006-08-17 | 2010-01-21 | Boehringer Ingelheim International Gmbh | Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors |
WO2008033572A1 (en) | 2006-09-15 | 2008-03-20 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
KR102044064B1 (ko) * | 2006-09-26 | 2019-11-12 | 노파르티스 아게 | S1p 조정제를 포함하는 제약 조성물 |
US8795721B2 (en) | 2006-12-18 | 2014-08-05 | Eatlittle Inc. | Device for delivery of a substance |
EP2124884B1 (de) * | 2006-12-22 | 2019-07-10 | Ironwood Pharmaceuticals, Inc. | Zusammensetzung mit gallensäurekomplexbildnern zur behandlung von erkrankungen der speiseröhre |
KR20080076382A (ko) * | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
CN101011393B (zh) * | 2007-02-16 | 2010-10-06 | 广州柏赛罗药业有限公司 | 厄贝沙坦胃内滞留型缓释药物组合物 |
DE102007026037A1 (de) | 2007-06-04 | 2008-12-11 | Lts Lohmann Therapie-Systeme Ag | Gastroretentives System mit Alginat-Körper |
US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
US8741918B2 (en) | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
HUP0700469A2 (en) * | 2007-07-09 | 2009-04-28 | Richter Gedeon Nyrt | Floating pharmaceutical composition of sustained release containing metronidazol |
JP2010534721A (ja) * | 2007-07-27 | 2010-11-11 | ディポメド,インコーポレイティド | パルス型胃滞留性製剤 |
WO2009023761A2 (en) * | 2007-08-14 | 2009-02-19 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions comprising ropinirole |
WO2009069089A1 (en) * | 2007-11-29 | 2009-06-04 | Ranbaxy Laboratories Limited | Levetiracetam controlled release composition |
EP2065038A1 (de) * | 2007-11-30 | 2009-06-03 | Pharnext | Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit |
WO2009097156A1 (en) * | 2008-02-01 | 2009-08-06 | Barr Laboratories, Inc. | Pharmaceutical capsules comprising extended release dipyridamole pellets |
US9457048B2 (en) | 2008-02-05 | 2016-10-04 | Wellosophy Corporation | Absorbent ingestible agents and associated methods of manufacture and use |
PT2276473T (pt) | 2008-04-18 | 2016-12-15 | Intec Pharma Ltd | Entrega de fármacos gastro-retentiva para carbidopa/levodopa |
ZA200903858B (en) * | 2008-06-19 | 2013-10-30 | Univ Of Witwatesrand Johannesburg | Pharmaceutical dosage form |
US20110129433A1 (en) * | 2008-06-26 | 2011-06-02 | Ironwood Pharmaceuticals, Inc. | Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory Disorders |
NZ588311A (en) * | 2008-07-24 | 2012-08-31 | Handa Pharmaceuticals Llc | Stabilized atypical antipsychotic formulation to treat psychiatric conditions |
MX340249B (es) | 2008-08-15 | 2016-07-01 | Depomed Inc | Composiciones farmacéuticas retentivas gástricas para tratamiento y prevención de transtornos del sistema nervioso central (cns). |
WO2010064139A2 (en) | 2008-12-04 | 2010-06-10 | Intec Pharma Ltd. | Zaleplon gastroretentive drug delivery system |
MX2011006463A (es) | 2008-12-19 | 2011-07-20 | Supernus Pharmaceuticals Inc | Metodo de tratamiento de agresion. |
WO2010084188A1 (en) * | 2009-01-26 | 2010-07-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of asthma |
US20100297195A1 (en) * | 2009-05-20 | 2010-11-25 | Ranbaxy Laboratories Limited | Controlled release lamotrigine formulations |
BRPI1009367A2 (pt) * | 2009-05-27 | 2016-03-08 | Dasan Medichem Co Ltd | tablete de camada múltipla |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
US20110104273A1 (en) * | 2009-11-05 | 2011-05-05 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine |
CN102791258B (zh) * | 2010-02-03 | 2018-05-08 | 图必制药公司 | 雷沙吉兰的延长释放制剂及其用途 |
WO2011101866A2 (en) * | 2010-02-17 | 2011-08-25 | Sun Pharma Advanced Research Company Ltd., | A method of treating a disease condition susceptible to baclofen therapy |
CA2793222C (en) * | 2010-03-31 | 2018-01-23 | Supernus Pharmaceuticals, Inc. | Stabilized formulations of cns compounds |
KR101270751B1 (ko) * | 2010-05-06 | 2013-06-07 | (주)비씨월드제약 | 위 체류 및 방출 조절을 위한 조성물 |
EP2575798B1 (de) | 2010-06-01 | 2017-08-09 | Rubicon Research Private Limited | Gastroretentive dosierungszubereitung von gaba analoga |
HUE026715T2 (en) | 2011-01-20 | 2016-07-28 | Bionevia Pharmaceuticals Inc | Modified release pharmaceutical composition comprising Epalrestat or a derivative thereof and methods of their use |
AT511671A1 (de) * | 2011-07-13 | 2013-01-15 | Bischof Georg Dr | Zusammensetzung zur erzeugung einer vorübergehenden okklusion des darms eines säugetiers |
KR101438546B1 (ko) * | 2011-08-26 | 2014-09-17 | 근화제약주식회사 | 프레가발린을 포함하는 서방성 제제 |
RU2489147C2 (ru) * | 2011-08-31 | 2013-08-10 | Людмила Петровна Лазурина | Фармацевтическая антибактериальная композиция для местного применения на основе активных биометаллокомплексов |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
CN102440976A (zh) * | 2011-12-21 | 2012-05-09 | 南京海陵中药制药工艺技术研究有限公司 | 依帕司他缓释片及其制备方法 |
KR102104635B1 (ko) * | 2012-04-18 | 2020-04-27 | 콘테라 파르마 에이피에스 | 운동 장애의 개선된 관리에 적합한 경구로 이용 가능한 약학적 제형 |
EP2950822B1 (de) * | 2013-01-30 | 2019-04-24 | Daewoong Co., Ltd. | Pharmazeutisches präparat zum schutz von wunden durch hämostase oder zur verhütung einer adhäsion im magen-darm-trakt |
JP2016520653A (ja) | 2013-06-05 | 2016-07-14 | シンクロニューロン インコーポレイテッド | アカンプロサート製剤、それを用いる方法、およびそれを含む合剤 |
FR3014692B1 (fr) * | 2013-12-18 | 2016-01-29 | Ethypharm Sa | Compositions pharmaceutiques orales a retention gastrique. |
WO2016001843A1 (en) * | 2014-06-30 | 2016-01-07 | Sun Pharmaceutical Industries Limited | Extended-release gastroretentive tablets of voglibose |
US10300032B2 (en) | 2015-02-20 | 2019-05-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
US10172800B2 (en) | 2015-02-20 | 2019-01-08 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form with enhanced pharmacokinetics |
EP3258916A1 (de) | 2015-02-20 | 2017-12-27 | Osmotica Kereskedelmi ES Szolgaltato KFT | Oralen darreichungsform mit kontrollierter freisetzung aus gaba-rezeptor-agonisten mit verbesserter pharmakokinetik |
US10987328B2 (en) | 2015-02-20 | 2021-04-27 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
RU2649834C1 (ru) * | 2016-07-06 | 2018-04-04 | Фармалидер С.А. | Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения |
WO2018011181A1 (en) | 2016-07-11 | 2018-01-18 | Contera Pharma Aps | Pulsatile drug delivery system for treating morning akinesia |
FR3054218B1 (fr) * | 2016-07-22 | 2020-03-06 | Universite De Rouen | Procede de dedoublement de sels de baclofene |
CN109922801B (zh) | 2016-09-09 | 2023-07-18 | 库蒂斯制药公司 | 甲硝唑和巴氯芬的混悬剂和稀释剂 |
US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
EP3345591A1 (de) | 2017-01-06 | 2018-07-11 | Oystershell NV | Orale dosierform für eine erhöhte löslichkeit eines schwerlöslichen wirkstoffs und verfahren zur herstellung |
WO2018127594A1 (en) * | 2017-01-06 | 2018-07-12 | Oystershell Nv | Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation |
JP6823539B2 (ja) * | 2017-05-26 | 2021-02-03 | 株式会社ファンケル | 胃内滞留性錠剤 |
ES2928071T3 (es) * | 2017-06-16 | 2022-11-15 | Amneal Complex Products Res Llc | Formas de dosificación gastrorretentiva para el suministro sostenido de fármacos |
US10588863B2 (en) * | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
US10987311B2 (en) * | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
KR102182559B1 (ko) * | 2017-09-08 | 2020-11-24 | 인시그니스 쎄라퓨틱스, 인코포레이티드 | 디피베프린을 사용하는 방법 |
US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
CN113476421B (zh) * | 2017-12-29 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 一种非布司他的控释组合物及其制备方法 |
CA3061382C (en) * | 2018-06-18 | 2020-12-15 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
AU2019289132A1 (en) * | 2018-06-19 | 2021-02-04 | Nanyang Technological University | Formulations of 5-hydroxy tryptophan (5-HTP) for better bioavailability for various indications |
CA3065695C (en) | 2018-06-27 | 2021-06-01 | Kashiv Biosciences, Llc | Self-regulating osmotic gastroretentive drug delivery systems |
JP7044649B2 (ja) * | 2018-06-28 | 2022-03-30 | 株式会社ファンケル | 胃内浮遊錠剤 |
WO2020011938A1 (en) | 2018-07-11 | 2020-01-16 | Medizinische Universität Wien | Glucocorticoids for the topical treatment of autoimmune gastritis |
US20220031623A1 (en) * | 2018-12-18 | 2022-02-03 | DDP Specialty Electronic Materials US, Inc. | A sustained release composition comprising a methylcellulose |
CA3139217A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
RU2751163C9 (ru) * | 2020-04-06 | 2021-10-20 | Общество С Ограниченной Ответственностью "Ниармедик Плюс" | Фармацевтическая композиция на основе макозинона для лечения туберкулеза, включая его формы с множественной и широкой лекарственной устойчивостью. |
WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
EP4436552A1 (de) * | 2021-11-25 | 2024-10-02 | Orexa B.V. | Gastroretentive orale dosiereinheit mit einem lokalanästhetikum |
CN114796142A (zh) * | 2022-04-08 | 2022-07-29 | 黄山学院 | 萘普生胃漂浮片及其制备方法 |
CN115444831B (zh) * | 2022-10-25 | 2023-08-22 | 南京康川济医药科技有限公司 | 一种依帕司他胃漂浮片及其制备方法 |
CN115721621A (zh) * | 2022-12-16 | 2023-03-03 | 杭州剂泰医药科技有限责任公司 | 一种依帕司他缓释制剂 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4101650A (en) | 1977-04-06 | 1978-07-18 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Pepstatin floating minicapsules |
SE8404467D0 (sv) * | 1984-09-06 | 1984-09-06 | Ferrosan Ab | Controlled-release medical preparations |
EP0205336B1 (de) | 1985-06-11 | 1991-09-11 | Teijin Limited | Oral-Arzneizubereitung mit Retardwirkung |
JPS62195323A (ja) | 1986-02-24 | 1987-08-28 | Eisai Co Ltd | 胃内滞留型粒子 |
US4772473A (en) * | 1986-06-16 | 1988-09-20 | Norwich Eaton Pharmaceuticals, Inc. | Nitrofurantoin dosage form |
JPH0798742B2 (ja) | 1986-07-03 | 1995-10-25 | ゼリア新薬工業株式会社 | 徐放性製剤組成物 |
US4851232A (en) * | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
IL87710A (en) * | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
US4892739A (en) * | 1988-04-25 | 1990-01-09 | Ciba-Geigy Corporation | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties |
US5096714A (en) * | 1988-06-28 | 1992-03-17 | Hauser-Kuhrts, Inc. | Prolonged release drug tablet formulations |
PH26730A (en) * | 1988-12-30 | 1992-09-28 | Ciba Geigy Ag | Coated adhesive tablets |
DE4406424A1 (de) | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandierbare Arzneiformen |
US5654005A (en) * | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
AU3990895A (en) * | 1995-12-05 | 1997-06-27 | Adcock Ingram Limited | Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic |
US6271278B1 (en) * | 1997-05-13 | 2001-08-07 | Purdue Research Foundation | Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties |
ES2248908T7 (es) * | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
IN186245B (de) * | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
AP1224A (en) | 1998-03-19 | 2003-11-14 | Bristol Myers Squibb Co | Biphasic controlled release delivery system for high solubility pharmaceuticals and method. |
GEP20043216B (en) * | 1998-09-14 | 2004-04-26 | Ranbaxy Laboratories Ltd In | Orally Administered Controlled Drug Delivery System |
FR2784583B1 (fr) | 1998-10-16 | 2002-01-25 | Synthelabo | Composition pharmaceutique a residence gastrique et a liberation controlee |
MXPA01006108A (es) * | 1998-12-17 | 2002-09-18 | Alza Corp | Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos. |
AU2199500A (en) * | 1998-12-23 | 2000-07-31 | Alza Corporation | Gastric retention dosage form having multiple layers |
AU6381000A (en) | 1999-07-29 | 2001-02-19 | Interneuron Pharmaceuticals, Inc. | Methods and compositions for alleviating stuttering |
AP2002002410A0 (en) | 1999-08-04 | 2002-03-31 | Ranbaxy Laboratories Ltd | Hydrodynamically Balancing Oral Drug Delivery System |
FR2797185B1 (fr) | 1999-08-06 | 2001-10-26 | Galenix Dev | Composition pharmaceutique flottante comprenant une phase active et une phase non active |
EP1095650A1 (de) | 1999-10-29 | 2001-05-02 | Universiteit Leiden | Zweiphasensystem mit kontrollierter Freigabe |
EP1411901B1 (de) * | 2001-07-04 | 2010-08-18 | Sun Pharma Advanced Research Company Ltd | Magenretentionssystem mit kontrollierter arzneimittelfreisetzung |
BRPI0413756A (pt) * | 2003-08-20 | 2006-10-31 | Xenoport Inc | composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica |
AU2007201808B8 (en) * | 2006-04-26 | 2013-09-05 | Sun Pharmaceutical Advanced Research Company Ltd | A method for alleviating signs and symptoms of spasticity |
-
2002
- 2002-07-04 EP EP02751608A patent/EP1411901B1/de not_active Expired - Lifetime
- 2002-07-04 PL PL02370793A patent/PL370793A1/xx unknown
- 2002-07-04 DE DE60237372T patent/DE60237372D1/de not_active Expired - Lifetime
- 2002-07-04 CN CN028128575A patent/CN1520286B/zh not_active Expired - Lifetime
- 2002-07-04 AT AT02751608T patent/ATE477795T1/de not_active IP Right Cessation
- 2002-07-04 JP JP2003516487A patent/JP4994570B2/ja not_active Expired - Fee Related
- 2002-07-04 AU AU2002355686A patent/AU2002355686B2/en not_active Ceased
- 2002-07-04 RU RU2003138075/15A patent/RU2325152C2/ru not_active IP Right Cessation
- 2002-07-04 HU HU0500795A patent/HUP0500795A3/hu unknown
- 2002-07-04 US US10/482,770 patent/US7776345B2/en active Active
- 2002-07-04 WO PCT/IN2002/000144 patent/WO2003011255A1/en active Application Filing
- 2002-07-04 BR BR0211317-1A patent/BR0211317A/pt not_active Application Discontinuation
- 2002-07-04 EP EP10165807A patent/EP2238975B1/de not_active Expired - Lifetime
- 2002-07-04 ES ES10165807T patent/ES2398348T3/es not_active Expired - Lifetime
- 2002-07-04 MX MXPA03012041A patent/MXPA03012041A/es active IP Right Grant
- 2002-07-04 KR KR10-2003-7016967A patent/KR20040018394A/ko not_active Application Discontinuation
- 2002-07-04 CA CA2452738A patent/CA2452738C/en not_active Expired - Fee Related
-
2004
- 2004-01-30 ZA ZA2004/00799A patent/ZA200400799B/en unknown
-
2009
- 2009-12-11 JP JP2009281402A patent/JP2010090161A/ja active Pending
-
2010
- 2010-08-13 US US12/856,097 patent/US8012496B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US7776345B2 (en) | 2010-08-17 |
RU2325152C2 (ru) | 2008-05-27 |
EP1411901A1 (de) | 2004-04-28 |
US8012496B2 (en) | 2011-09-06 |
HUP0500795A3 (en) | 2008-04-28 |
RU2003138075A (ru) | 2005-06-10 |
JP2010090161A (ja) | 2010-04-22 |
ES2398348T3 (es) | 2013-03-15 |
EP2238975B1 (de) | 2012-12-05 |
JP2004538301A (ja) | 2004-12-24 |
BR0211317A (pt) | 2004-12-14 |
US20040180088A1 (en) | 2004-09-16 |
EP1411901B1 (de) | 2010-08-18 |
CN1520286A (zh) | 2004-08-11 |
HUP0500795A2 (en) | 2007-02-28 |
PL370793A1 (en) | 2005-05-30 |
US20100305208A1 (en) | 2010-12-02 |
KR20040018394A (ko) | 2004-03-03 |
ZA200400799B (en) | 2005-07-27 |
CN1520286B (zh) | 2010-12-01 |
CA2452738A1 (en) | 2003-02-13 |
ATE477795T1 (de) | 2010-09-15 |
JP4994570B2 (ja) | 2012-08-08 |
EP2238975A1 (de) | 2010-10-13 |
MXPA03012041A (es) | 2004-03-26 |
AU2002355686B2 (en) | 2007-11-29 |
WO2003011255A1 (en) | 2003-02-13 |
CA2452738C (en) | 2011-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60237372D1 (de) | Magenretentionssystem mit kontrollierter arzneimittelfreisetzung | |
DE69917866D1 (de) | Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe | |
ATE269709T1 (de) | Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff | |
ATE251449T1 (de) | Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe | |
NO995313D0 (no) | Mikroartikler nyttige som ultrasoniske kontrastmidler og til levering av legemidler i blodbanen | |
WO2003028660A3 (en) | Drug delivery devices and methods | |
HUP0002935A2 (hu) | Gyomorban visszatartott, szabályozott hatóanyag kibocsátású mikrogömböcskék javított gyógyszeradagolás elősegítésére | |
NZ512683A (en) | Taste-masked pharmaceutical particles that are suitable for making chewable tablets | |
WO2003103637A3 (en) | MODIFIED RELEASE MULTIPLE UNIT DRUG DELIVERY SYSTEMS | |
DE69619668D1 (de) | Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon | |
CY1106072T1 (el) | Φαρμακευτικη μορφη δοσης παρατεταμενης αποδεσμευσης απο του στοματος | |
ATE264666T1 (de) | Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe | |
AP2001002237A0 (en) | Hydrogel-driven drug dosage form. | |
MY130332A (en) | Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer | |
IL154731A0 (en) | Ion-strength independent sustained release pharmaceutical formulation | |
WO2006030402A3 (en) | Dual compartment osmotic delivery device | |
CA2417887A1 (en) | Particulate composition of eletriptan | |
ATE306910T1 (de) | Tablette mit verlängerter wirkstoffabgabe im magen | |
WO2003096968A3 (en) | Oral osmotic controlled drug delivery system | |
WO2003026555A3 (en) | Floating osmotic device for controlled release drug delivery | |
EA200401145A1 (ru) | Оральная фармацевтическая композиция с модифицированным высвобождением | |
AR042822A1 (es) | Sistema de administracion controlada de farmacos de retencion gastrica con cobertura enterica | |
UY27345A1 (es) | Formulación farmacéutica. | |
CA2243863A1 (en) | Gastrointestinal drug delivery system |